CS202229B1 - 2-isopropyl-6-fluor-9-/3-dimethylaminopropyliden/thioxanthene - Google Patents
2-isopropyl-6-fluor-9-/3-dimethylaminopropyliden/thioxanthene Download PDFInfo
- Publication number
- CS202229B1 CS202229B1 CS243578A CS243578A CS202229B1 CS 202229 B1 CS202229 B1 CS 202229B1 CS 243578 A CS243578 A CS 243578A CS 243578 A CS243578 A CS 243578A CS 202229 B1 CS202229 B1 CS 202229B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- isopropyl
- thioxanthene
- mixture
- dimethylaminopropyliden
- fluor
- Prior art date
Links
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims description 5
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 claims description 4
- BSQQVIBIPIIXHP-UHFFFAOYSA-N 3-(6-fluoro-2-propan-2-ylthioxanthen-9-ylidene)-n,n-dimethylpropan-1-amine Chemical compound FC1=CC=C2C(=CCCN(C)C)C3=CC(C(C)C)=CC=C3SC2=C1 BSQQVIBIPIIXHP-UHFFFAOYSA-N 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- -1 2-isopropyl-6-fluoro-3- (3-dimethylaminopropylidene) thioxanthene Chemical compound 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002903 catalepsic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RRKPMLZRLKTDQV-UHFFFAOYSA-N 2-bromo-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1Br RRKPMLZRLKTDQV-UHFFFAOYSA-N 0.000 description 2
- YDUHLTPGUJFFGC-UHFFFAOYSA-N 4-fluoro-2-(4-propan-2-ylphenyl)sulfanylbenzoic acid Chemical compound C1=CC(C(C)C)=CC=C1SC1=CC(F)=CC=C1C(O)=O YDUHLTPGUJFFGC-UHFFFAOYSA-N 0.000 description 2
- APDUDRFJNCIWAG-UHFFFAOYSA-N 4-propan-2-ylbenzenethiol Chemical compound CC(C)C1=CC=C(S)C=C1 APDUDRFJNCIWAG-UHFFFAOYSA-N 0.000 description 2
- GRHJEVGZPCKOAF-UHFFFAOYSA-N 6-fluoro-2-propan-2-ylthioxanthen-9-one Chemical compound FC1=CC=C2C(=O)C3=CC(C(C)C)=CC=C3SC2=C1 GRHJEVGZPCKOAF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- STGNLGBPLOVYMA-TZKOHIRVSA-N (z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O STGNLGBPLOVYMA-TZKOHIRVSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NGPAITITALWALP-UHFFFAOYSA-M magnesium;n,n-dimethylpropan-1-amine;chloride Chemical compound [Mg+2].[Cl-].CN(C)CC[CH2-] NGPAITITALWALP-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Tento vynález se týká 2-isopropyl-6-fluor9- (3-dimethylaminopropyliden) thioxanthenu vzorce I (I)This invention relates to 2-isopropyl-6-fluoro-3- (3-dimethylaminopropylidene) thioxanthene of formula I (I)
a jeho solí.and its salts.
Látka I a její soli se vyznačují centrálně neurotropní účinností a jsou použitelné v psychiatrii a neurologii jako léčiva. Jejich typickou vlastností je centrálně tlumivá účinnost, která není doprovázena kataleptickým účinkem. Jsou to tedy trankvilizéry, u kterých lze očekávat minimální vedlejší účinky. Jsou použitelné k zklidnění neklidných neurotických pacientů a působí proti fóbiím, pocitu strachu a anxiositě.Compound I and its salts have central neurotrophic activity and are useful as drugs in psychiatry and neurology. Their typical property is centrally damping activity, which is not accompanied by cataleptic effect. They are therefore tranquilizers for which minimal side effects can be expected. They are useful for calming restless neurotic patients and counteract phobias, fear and anxiety.
K farmakologickému hodnocení na zvířatech (myši, krysy) bylo použito hydrogenmaleinátu látky I. Je to látka s nízkou jedovatostí. Její střední smrtná dávka pro myši při orálním podání LD50 je 280 mg/kg. Centrálně tlumivý účinek lze zjistit v prvé řadě v testu rotující tyčky na myších, ve kterém orální dávka 6,3 mg/kg vyvolává ataxii (poruchu pohybové koordinace) u 50 % zvířat (dávka ED50). Tento účinek látky je prolongovaný, protože ješte za 24 hodin po podání je ataxie prokazatelná u 20 % zvířat (rozsah dávek, 2,5 až 20 mg/kg). Další test, kterým lze prokázat tlumivý účinek látky, je paprsková metoda sledování ovlivnění spontánní lokomotorické aktivity myší. V tomto testu je střední účinná dávka D50 rovnaFor the pharmacological evaluation in animals (mice, rats), hydrogen maleate of substance I was used. It is a substance of low toxicity. Its mean lethal dose for mice by oral administration of LD 50 is 280 mg / kg. The centrally depressant effect can be found primarily in a rotating rod test in mice in which an oral dose of 6.3 mg / kg induces ataxia (impaired locomotor coordination) in 50% of the animals (ED 50 dose). This effect of the substance is prolonged because at 24 hours after administration, ataxia is detectable in 20% of animals (dose range, 2.5 to 20 mg / kg). Another test that can demonstrate the depressant effect of a substance is the beam method of monitoring the effect of spontaneous locomotor activity in mice. In this test, the median effective dose of D 50 is equal to
1,5 mg/kg; tato dávka snižuje lokomotorickou aktivitu zvířat na 50 %. Látka I je současně prakticky neúčinná katalepticky, protože v testu katalepsie u krys je její střední účinná dávka vyšší než 50 mg/kg při orálním podání. Ve shodě s tím neovlivňuje orální dávka 40 mg/kg apomorfinové stereotypie a agitaci u krys. Obojí nasvědčuje tomu, že látka není neuroleptikem, ale nekataleptickým trankvilizérem.1.5 mg / kg; this dose reduces the locomotor activity of the animals to 50%. At the same time, Compound I is virtually ineffective cataleptically since, in the rat catalepsy test, its median effective dose is greater than 50 mg / kg when administered orally. Accordingly, an oral dose of 40 mg / kg did not affect apomorphine stereotype and agitation in rats. Both indicate that the substance is not a neuroleptic but a non-cataleptic tranquilizer.
Látka I (ve formě uvedeného hydrogenmaleinátu) má dále určitou antimikrobiální účinnost. V testech in vitro působí antimikrobiálně vůči dále uvedeným mikroorganismům, přičemž připojená čísla jsou minimální inhibiční koncentrace v ^g/ml: Streptococcus faecalis, 25; Staphylococcus pyogenes aureus, 25; Mycobacterium tuberculosis H37Rv, 5; Saccharomyces pasterianus, 6,2; Trichophyton mentagrophytes, 25; Candida alblcans, 100; Aspergillus niger, 50.Furthermore, compound I (in the form of said hydrogen maleate) has some antimicrobial activity. In in vitro assays it has an antimicrobial action against the following microorganisms, with the appended numbers being the minimum inhibitory concentration in µg / ml: Streptococcus faecalis, 25; Staphylococcus pyogenes aureus, 25; Mycobacterium tuberculosis H37Rv.5; Saccharomyces pasterianus, 6.2; Trichophyton mentagrophytes, 25; Candida alblcans 100; Aspergillus niger, 50.
V příkladu provedení je popsán jeden z možných způsobů přípravy látky I a jejích solí. Tento způsob vychází ze známéIn an exemplary embodiment, one possible method of preparing Compound I and its salts is described. This method is based on the known
202 229202 229
202 229 kyseliny 2-brom-4-fluorbenzoové (M. Rajšner a spol., Collect. Czech. Chem. Commun. 40, 728, 1975) a z rovněž známého 4-isopropylthiofenolu (V. Valenta a spol., Collect. Czech, Chem. Commun. 39, 797, 1974). V prvním stupni se obě látky kondensuji zahříváním v dimethylformamidu za přítomnosti bezvodého uhličitanu draselného a mědi jako katalysátoru. Tímto způsobem se získá kyselina 4-fluor-2- (4-isopropylf eny lthio J benzoová. V dalším stupni se tato kyselina cyklisuje působením koncentrované kyseliny sírové při 100 °C na 2-isopropyl-6-fluorthioxanthon. V dalším stupni se tento keton podrobí působení 3-dimethylaminopropylmagnesiumchloridu, nejlépe v prostředí tetrahydrofuranu. Hydrolysou primárního produktu se získá krystalický 2-isopropyl6-fluor-9-( 3-dimethylaminopropyl }thioxanthen-9-ol. Poslední reakcí synthetického postupu je kysele katalysovaná dehydratace jmenovaného terciárního alkoholu. Provede se zahříváním se zředěnou minerální kyselinou sírovou nebo kyselinou chlorovodíkovou. Báze I, tj. 2-isopropyl-6-fluor-9-(3-dimethylaminopropylidenjthioxanthen, se získá jako olejovitá směs geometrických isomerů, tj. isomeru cis a isomeru trans. Tento vynález se týká obou geometrických isomerů. Olejovitá báze poskytuje neutralisací kyselinou maleinovou krystalický hydrogenmaleinát, který se opakovanou krystalisací získá v prakticky jednotné formě, a na základě absence kataleptického efektu lze této látce přisoudit konfiguraci trans. Tata látka má b. t. 127 až 132 °C a ve vodě se rozpouští při teplotě místnosti na 2% roztok. Lépe je rozpustná v ethanolu a z roztoku se vylučuje přídavkem etheru. V matečných louzích se hromadí druhý geometrický isomer, tj. isomer cis.202 229 2-bromo-4-fluorobenzoic acid (M. Rajšner et al., Collect. Czech. Chem. Commun. 40, 728, 1975) and also known 4-isopropylthiophenol (V. Valenta et al., Collect. Chem. Commun. 39, 797 (1974). In the first step, both compounds are condensed by heating in dimethylformamide in the presence of anhydrous potassium carbonate and copper catalyst. There was thus obtained 4-fluoro-2- (4-isopropylphenylthio) benzoic acid, which was cyclized by treatment with concentrated sulfuric acid at 100 DEG C. to give 2-isopropyl-6-fluorothioxanthone. Hydrolysis of the primary product yields crystalline 2-isopropyl-6-fluoro-9- (3-dimethylaminopropyl) thioxanthen-9-ol. Base I, i.e. 2-isopropyl-6-fluoro-9- (3-dimethylaminopropylidene) thioxanthene, is obtained as an oily mixture of geometric isomers, i.e. cis and trans isomers. The oily base provides crystalline hydrogen by neutralization with maleic acid maleate, which is obtained in practically uniform form by repeated crystallization and, owing to the absence of a cataleptic effect, can be attributed to the trans configuration. 127 DEG-132 DEG C. and dissolved in water at room temperature to a 2% solution. It is better soluble in ethanol and is eliminated from the solution by addition of ether. The second geometric isomer, ie the cis isomer, accumulates in the mother liquors.
PříkladExample
Ve 40 ml dimethylformamidu se rozpustí 15 g 4-isopropylthiofenolu a postupně se přidá 19,6 g kyseliny 2-brom-4-fluorbenzoové, 25 g bezvodého uhličitanu draselného a 1,5 g čerstvě vyredukované mědi. Směs se za míchání zahřívá 3 hodiny na 150 °C. Po ochlazení se silně zředí vodou, okyselí se zředěnou kyselinou chlorovodíkovou a vyloučený produkt se isoluje extrakcí chloroformem. Extrakt se vysuší síranem sodným a odpaří. Krystalisací zbytku ze směsi benzenu a petroletheru nebo z cyklohexanu se získá 18,3 g (71 %] kyseliny 4-fluor-2(4-isopropylfenylthio) benzoové, která po rekrystalisaci z ethanolu má b. t. 201 až 202 stupňů Celsia.15 g of 4-isopropylthiophenol are dissolved in 40 ml of dimethylformamide and 19.6 g of 2-bromo-4-fluorobenzoic acid, 25 g of anhydrous potassium carbonate and 1.5 g of freshly reduced copper are gradually added. The mixture was heated to 150 ° C with stirring for 3 hours. After cooling, it is strongly diluted with water, acidified with dilute hydrochloric acid and the precipitated product is isolated by extraction with chloroform. The extract was dried over sodium sulfate and evaporated. Crystallization of the residue from a mixture of benzene and petroleum ether or cyclohexane gave 18.3 g (71%) of 4-fluoro-2- (4-isopropylphenylthio) benzoic acid which, after recrystallization from ethanol, had mp 201-202 degrees Celsius.
Směs 18,2 g předešlé kyseliny a 100 ml konc. kyseliny sírové se zahřívá 35 minut na 100 °C. Po ochlazení se vlije do 750 ml vody, vyloučený pevný produkt se odsaje, rozpustí se v chloroformu, roztok se promyje 5% roztokem hydroxidu sodného, vysuší se uhličitanem draselným a odpaří. Získá se 16,1 (94%) 2-isopropyl-6-fluorthioxanthonu, který po krystalisací z ethanolu má b. t. 116 až 117 °C.A mixture of 18.2 g of the previous acid and 100 ml of conc. of sulfuric acid was heated to 100 ° C for 35 minutes. After cooling, it is poured into 750 ml of water, the precipitated solid product is filtered off with suction, dissolved in chloroform, washed with 5% sodium hydroxide solution, dried over potassium carbonate and evaporated. 16.1 (94%) of 2-isopropyl-6-fluorothioxanthone are obtained, which, after crystallization from ethanol, has a melting point of 116-117 ° C.
Reakcí 2,7 g hořčíku s 14 g 3-dimethylaminopropylchloridu v 35 mi absolutního tetrahydrofuranu se získá roztok Grignardova činidla, tj. 3-dimethylaminopropylmagnesiumchloridu. K tomuto roztoku se při teplotě místnosti za míchání přikape roztokReaction of 2.7 g of magnesium with 14 g of 3-dimethylaminopropyl chloride in 35 ml of absolute tetrahydrofuran gives a solution of the Grignard reagent, i.e. 3-dimethylaminopropylmagnesium chloride. To this solution was added dropwise at room temperature with stirring
15,6 g předešlého ketonu v dalších 35 ml tetrahydrofuranu. Směs se míchá 30 minut při teplotě místnosti a za chlazení vodou se rozloží přikapáním 100 ml 20% roztoku chloridu amonného. Směs se potom extrahuje benzenem. Vodná fáze se oddělí, organická fáze se vysuší uhličitanem draselným a odpaří za sníženého tlaku. Krystalisací odparku ze směsi 42 ml benzenu a 100 ml petroletheru se získá 12,0 g (58%) 2-isopropyl-6-f luor-9- (3-dimethylaminopropyl ] thioxanthen-9-olu, který v čistém stavu taje při 146 až 148 °C.15.6 g of the previous ketone in another 35 ml of tetrahydrofuran. The mixture was stirred at room temperature for 30 minutes and quenched by dropwise addition of 100 ml of 20% ammonium chloride solution under cooling with water. The mixture is then extracted with benzene. The aqueous phase is separated, the organic phase is dried over potassium carbonate and evaporated under reduced pressure. Crystallization of the residue from a mixture of 42 ml of benzene and 100 ml of petroleum ether gave 12.0 g (58%) of 2-isopropyl-6-fluoro-9- (3-dimethylaminopropyl) thioxanthen-9-ol, which melted at 146 DEG C. up to 148 ° C.
K roztoku 9 ml kyseliny sírové v 90 ml vody se přidá 11,5 g předešlého aminoalkoholu a směs se vaří 1 hodinu pod zpětným chladičem. Po ochlazení se zředí vodou, zalkalisuje se hydroxidem amonným a báze se isoluje extrakcí etherem. Extrakt se vysuší uhličitanem draselným a odpaří. Získá se 11 g olejovlté směsi cis- a trans-2-isopropyl-6-fluor-9- (3-dimethylaminopropyliden)thioxanthenu. Neutralisací kyselinou maleinovou v ethanolu a přídavkem etheru se vyloučí 10,0 g krystalického hydrogenmaleinátu s b. t. 125 až 130 °C. Po rekrystalisaci ze směsi ethanolu a etheru je tato sůl prakticky homogenní a taje při 127 až 132 °C.To a solution of 9 ml of sulfuric acid in 90 ml of water was added 11.5 g of the preceding aminoalcohol and the mixture was refluxed for 1 hour. After cooling, it is diluted with water, basified with ammonium hydroxide and the base isolated by extraction with ether. The extract was dried over potassium carbonate and evaporated. 11 g of an oily mixture of cis- and trans-2-isopropyl-6-fluoro-9- (3-dimethylaminopropylidene) thioxanthene are obtained. By neutralization with maleic acid in ethanol and addition of ether, 10.0 g of crystalline hydrogen maleate having a melting point of 125 DEG-130 DEG C. were obtained. After recrystallization from a mixture of ethanol and ether, the salt is practically homogeneous and melts at 127-132 ° C.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS243578A CS202229B1 (en) | 1978-04-14 | 1978-04-14 | 2-isopropyl-6-fluor-9-/3-dimethylaminopropyliden/thioxanthene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS243578A CS202229B1 (en) | 1978-04-14 | 1978-04-14 | 2-isopropyl-6-fluor-9-/3-dimethylaminopropyliden/thioxanthene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS202229B1 true CS202229B1 (en) | 1980-12-31 |
Family
ID=5361499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS243578A CS202229B1 (en) | 1978-04-14 | 1978-04-14 | 2-isopropyl-6-fluor-9-/3-dimethylaminopropyliden/thioxanthene |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS202229B1 (en) |
-
1978
- 1978-04-14 CS CS243578A patent/CS202229B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2537070C2 (en) | ||
| US4196292A (en) | 6-Substituted amiloride derivatives | |
| CS196893B1 (en) | 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines | |
| CS202229B1 (en) | 2-isopropyl-6-fluor-9-/3-dimethylaminopropyliden/thioxanthene | |
| NO743135L (en) | ||
| US4247715A (en) | 2-Alkynyl-5-indanyloxyacetic acids | |
| US3598861A (en) | 2-(5'-phenyl-m-terphenyl - 4 - yloxy) lower aliphatic monocarbocyclic acids and esters thereof | |
| US4334088A (en) | 2-Alkynyl-5-indanyloxyacetic acids | |
| US3481944A (en) | Certain aryl and hetero aryl oximes and 4-benzoyloxycyclohexanone oxime | |
| US3598862A (en) | 2 - (4 - (3',5' - diphenylcyclohexyl) - phenoxy)lower aliphatic monocarbocylic acids and esters thereof | |
| CS236550B1 (en) | Process for the preparation of the dibenzo (b, e) piperazinoalkanols esters of the thiepine series and their maleic acid salts | |
| Snyder et al. | Amine Replacement Reactions of α-Dimethylaminomethyl-β-methoxynaphthalene | |
| US4291168A (en) | Silylated indanyloxyacetates | |
| US3996286A (en) | α-Bromo-pivaloyl toluenes | |
| CS236449B1 (en) | Aminoalcohol 2-chlorodibenzo (b, e) thiepine series and its salts | |
| DE1468531C2 (en) | Right-handed hexahydroindanpropionic acid derivatives and process for their preparation | |
| US3321530A (en) | 3, 4-dihydro-2, 5-dimethoxynaphthalene | |
| FI61865B (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBAR 2-ETYL-5-INDANAETTIKYYRA | |
| US3213109A (en) | Aminoalkanol esters of sulfolanylalkanoic acids | |
| CS217881B1 (en) | A process for preparing a novel amine derived from 2-chloro-11H-dibenz (b, f -1,4-oxathiepine) | |
| NO780494L (en) | METHYL-2 PRODUCT PROCEDURES FENOXY-2 PROPION ACID DERIVATIVES | |
| CS225570B1 (en) | Preparation of steroisomeric 11-/3-dimetylaminepropyl/-10,11-dihydrodibenzo/b,f/thiepine-10-carbonitriles and their salts | |
| NO140717B (en) | PROCEDURE FOR THE PREPARATION OF 5-CYCLOALKYL-6-HALOGEN-BEFORE-1-CARBOXYLIC ACID AND SALTS THEREOF | |
| CS236384B1 (en) | Polychlorinated 9- (3-dimethylaminopropylidane) thioxanthenes, their salts and their method of preparation | |
| CS217949B1 (en) | 4,5-dihydrothieno (2,3-b) -1-benzothiepine derivative and its salts |